Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week's issue of Science. The article is available at http://www.sciencemag.org. ...